BPG is committed to discovery and dissemination of knowledge
Featured Articles
2/28/2025 11:47:27 AM | Browse: 403 | Download: 686
 |
Received |
|
2024-08-09 03:16 |
|
Peer-Review Started |
|
2024-08-11 14:55 |
|
First Decision by Editorial Office Director |
|
2024-11-22 11:29 |
|
Return for Revision |
|
2024-11-22 11:29 |
|
Revised |
|
2024-12-06 10:31 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-01-09 02:58 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-02-07 02:57 |
|
Articles in Press |
|
2025-02-07 02:57 |
|
Edit the Manuscript by Language Editor |
|
2025-02-14 23:10 |
|
Typeset the Manuscript |
|
2025-02-20 08:16 |
|
Publish the Manuscript Online |
|
2025-02-28 10:47 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Minireviews |
| Article Title |
T helper 17 cells and interleukin-17 immunity in type 1 diabetes: From pathophysiology to targeted immunotherapies
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Georgi Vasilev, Maria Kokudeva, Elina Siliogka, Nathalia Padilla, Russka Shumnalieva, David Della-Morte, Camillo Ricordi, Antoaneta Mihova, Marco Infante and Tsvetelina Velikova |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria |
BG-RRP-2.004-0008 |
|
| Corresponding Author |
Georgi Vasilev, Assistant Professor, MD, PhD, Department of Clinic of Neurology and Emergency Medicine, UMHAT "Sv Georgi", Blvd Peshtersko Shose 66, Plovdiv 4000, Bulgaria. vvasilev.georgi@gmail.com |
| Key Words |
Type 1 diabetes; T helper 17 cells; Interleukin-17; T helper 1 cells; Regulatory T cells; Anti-interleukin-17 treatment; Th17-targeted treatment |
| Core Tip |
Recent research has identified Th17 cells and their primary effector cytokine, interleukin (IL)-17, as key players in the pathophysiology of type 1 diabetes (T1D). Th17 cells contribute to the autoimmune responses directed against pancreatic beta cells in T1D, promoting insulitis and beta-cell destruction. Understanding the role of Th17 cells and IL-17 in T1D pathophysiology offers new opportunities for targeted immunotherapies, which aim to modulate the altered immune responses and preserve residual beta-cell function in presymptomatic and new-onset T1D. Therefore, Th17 cell- and IL-17-targeted interventions may potentially represent future disease-modifying therapies able to improve clinical outcomes in patients with T1D at different stages of the disease. |
| Publish Date |
2025-02-28 10:47 |
| Citation |
Vasilev G, Kokudeva M, Siliogka E, Padilla N, Shumnalieva R, Della-Morte D, Ricordi C, Mihova A, Infante M, Velikova T. T helper 17 cells and interleukin-17 immunity in type 1 diabetes: From pathophysiology to targeted immunotherapies. World J Diabetes 2025; 16(4): 99936 |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i4/99936.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i4.99936 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
